Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01276054 · ClinicalTrials.gov registry record · Phase 2
Sentinel and/or Axillary Lymph Node Biopsy With or Without Axillary Reverse Mapping in Reducing Incidence and Severity of Arm Lymphedema in Stage 0-2 Patients.
A Phase 2 study, sponsored by University of Southern California.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT01276054 is a Phase 2 study that was terminated before completion, run by University of Southern California. The registered enrollment target is 4 participants.
The verdict
NCT01276054, a Phase 2 study, was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
Lymph node biopsy followed by axillary reverse mapping may reduce the incidence and severity of arm lymphedema. This randomized phase II trial is studying how well sentinel and/or axillary lymph node biopsy with or without axillary reverse mapping works in reducing incidence and severity of lymphedema in patients with resectable stage 0-II breast cancer
Interventions
- PROCEDURE sentinel lymph node biopsy
- DRUG indocyanine green solution
- DRUG methylene blue
- RADIATION technetium Tc 99m sulfur colloid
- PROCEDURE axillary lymph node biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2010-12 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01276054
The ClinicalTrials.gov registry entry for NCT01276054 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which sentinel lymph node biopsy is the first listed.
NCT01276054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01276054 about?
NCT01276054 is a clinical study titled "Sentinel and/or Axillary Lymph Node Biopsy With or Without Axillary Reverse Mapping in Reducing Incidence and Severity of Arm Lymphedema in Stage 0-2 Patients.". Lymph node biopsy followed by axillary reverse mapping may reduce the incidence and severity of arm lymphedema. This randomized phase II trial is studying how well sentinel and/or axillary lymph node biopsy with or without axillary reverse mapping works in reducing incidence and severity of lymphede...
What is the current status of trial NCT01276054?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2010-12. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01276054?
The interventions under investigation include: sentinel lymph node biopsy (PROCEDURE), indocyanine green solution (DRUG), methylene blue (DRUG), technetium Tc 99m sulfur colloid (RADIATION), axillary lymph node biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT01276054?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.